Physician profile
Catherine A Daum
NPI 1497863476
$14,523.79
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,266 · 2020: $5,851 · 2021: $408.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12,361.48 | 2019-2020 | |
| Novo Nordisk INC | $384.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.45 | 2019-2021 | |
| Amgen INC. | $233.36 | 2019-2021 | |
| Glaxosmithkline, LLC. | $174.15 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $117.98 | 2019-2021 | |
| Amarin Pharma, INC. | $108.49 | 2019-2021 | |
| Lilly USA, LLC | $103.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $85.27 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $78.60 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.08 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $75.53 | 2019-2020 | |
| Esperion Therapeutics, INC. | $65.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $49.54 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.14 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $40.03 | 2019 | |
| Ironwood Pharmaceuticals, INC | $37.58 | 2019-2020 | |
| Genzyme Corporation | $35.89 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $30.73 | 2021 | |
| Abbvie INC. | $25.46 | 2020-2021 | |
| Daiichi Sankyo INC. | $19.79 | 2019 | |
| Grifols USA, LLC | $15.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.80 | 2019 | |
| Currax Pharmaceuticals LLC | $13.71 | 2019 | |
| Genentech USA, INC. | $11.99 | 2019 | |
| Hikma Pharmaceuticals USA | $11.61 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.11 | 2021 | |
| Merck Sharp & Dohme LLC | $11.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Daum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.